{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:40:17Z","timestamp":1772797217794,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.urology.2020.08.004","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T08:03:52Z","timestamp":1597392232000},"page":"199-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?"],"prefix":"10.1016","volume":"147","author":[{"given":"Karl H.","family":"Tully","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander P.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke J.","family":"Krimphove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Mossanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Noldus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guru P.","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quoc-Dien","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2020.08.004_bib0001","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00428-015-1739-2","article-title":"Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old","volume":"466","author":"Comperat","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.urology.2020.08.004_bib0002","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.08.004_bib0003","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.08.004_bib0004","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.6004\/jnccn.2018.0072","article-title":"NCCN guidelines insights: bladder cancer, version 5.2018","volume":"16","author":"Flaig","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2020.08.004_bib0005","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.08.004_bib0006","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"Jarvinen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.08.004_bib0007","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.08.004_bib0008","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.eururo.2014.11.031","article-title":"Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guerin","volume":"67","author":"Mostafid","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.08.004_bib0009","volume":"2019","year":"2019"},{"key":"10.1016\/j.urology.2020.08.004_bib0010","article-title":"Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC)","author":"Werntz","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2020.08.004_bib0011","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11934-016-0625-z","article-title":"High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage","volume":"17","author":"Veeratterapillay","year":"2016","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urology.2020.08.004_bib0012","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","article-title":"Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?","volume":"53","author":"Denzinger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.08.004_bib0013","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.urolonc.2017.08.008","article-title":"Secondary data sources for health services research in urologic oncology","volume":"36","author":"Cole","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2020.08.004_bib0014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/096228029600500102","article-title":"Box-Jenkins modelling in medical research","volume":"5","author":"Helfenstein","year":"1996","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.urology.2020.08.004_bib0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/picr.PICR_87_17","article-title":"Common pitfalls in statistical analysis: Logistic regression","volume":"8","author":"Ranganathan","year":"2017","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.urology.2020.08.004_bib0016","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2020.08.004_bib0017","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMp1212468","article-title":"The impact of drug shortages on children with cancer\u2013the example of mechlorethamine","volume":"367","author":"Metzger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2020.08.004_bib0018","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.urology.2007.10.041","article-title":"Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy","volume":"71","author":"Gupta","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.08.004_bib0019","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.08.004_bib0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.08.004_bib0021","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with gleason score 9-10 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2020.08.004_bib0022","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2016.11.006","article-title":"New prostate cancer grading system predicts long-term survival following surgery for gleason score 8-10 prostate cancer","volume":"71","author":"Ham","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.08.004_bib0023","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/pcan.2017.35","article-title":"Contemporary management of men with high-risk localized prostate cancer in the United States","volume":"20","author":"Weiner","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urology.2020.08.004_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119494","article-title":"Trends and outcome from radical therapy for primary non-metastatic prostate cancer in a UK population","volume":"10","author":"Greenberg","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.urology.2020.08.004_bib0025","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1371\/journal.pmed.0040284","article-title":"Optimal management of high-risk T1G3 bladder cancer: a decision analysis","volume":"4","author":"Kulkarni","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.urology.2020.08.004_bib0026","doi-asserted-by":"crossref","first-page":"94","DOI":"10.21037\/tau.2018.09.09","article-title":"Device-assisted intravesical therapy for non-muscle invasive bladder cancer","volume":"8","author":"Hendricksen","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urology.2020.08.004_bib0027","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urology.2020.08.004_bib0028","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2019.37.7_suppl.350","article-title":"Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-gu\u00e9rin (BCG)","volume":"37","author":"Balar","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2020.08.004_bib0029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2007.06912.x","article-title":"The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy","volume":"100","author":"Lambert","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.08.004_bib0030","doi-asserted-by":"crossref","first-page":"e2176","DOI":"10.1097\/MD.0000000000002176","article-title":"Low-dose versus standard dose of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"94","author":"Zeng","year":"2015","journal-title":"Medicine (Baltimore)"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520309833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520309833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:20:05Z","timestamp":1758766805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429520309833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":30,"alternative-id":["S0090429520309833"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2020.08.004","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2020.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}